💨 Abstract

Sun Pharmaceutical Industries and Philogen have announced a global partnership to commercialize Fibromun, an anti-cancer immunotherapy product. Fibromun is under investigation for treating soft tissue sarcoma and glioblastoma, with significant unmet medical needs. Under the agreement, Sun Pharma will commercialize Fibromun globally, while Philogen will continue clinical trials, seek regulatory approvals, and manufacture the product.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖